In 103 people living with HIV analysed per protocol (of 110 randomised), high-dose quadrivalent inactivated influenza vaccine gave seroprotection to all four strains in 61.5% vs 39.2% with standard dose (p=0.02); adverse events were 55.8% vs 58.8%.
RCTn = 110
Laoharattanahirun et al. Immunogenicity and safety of high-dose versus standard-dose quadrivalent inactivated influenza vaccine in patients living with HIV: a randomized controlled trial